Thomas J. George, MD, regarding the NRG-GI002 trial as presented at ASCO GI 2021
Dr. George, Director, GI Oncology Program, University of Florida, discusses primary results from the NRG-GI002 trial as presented at the 2021 ASCO Gastrointestinal Cancers Symposium
Thomas J. George, MD, elaborates on the design of the NRG-GI002 clinical trial
Dr. George, Director, GI Oncology Program, University of Florida, elaborates on the design of the NRG-GI002 clinical trial
Thomas J. George, MD, considers results from the experimental arms of the NRG-GI002 clinical trial
Dr. George, Director, GI Oncology Program, University of Florida, considers results from the experimental arms of the NRG-GI002 clinical trial
Thomas J. George, MD, discusses the side effect profile of pembrolizumab in the NRG-GI002 trial
Dr. George, Director, GI Oncology Program, University of Florida, discusses the side effect profile of pembrolizumab in the NRG-GI002 trial as presented at the 2021 Gastrointestinal Cancers Symposium
Thomas J. George, MD, on the evolving treatment landscape of locally advanced rectal cancer
Dr. George, Director, GI Oncology Program, University of Florida, speculates on the evolving treatment landscape of locally advanced rectal cancer and whether potential improvements in outcomes are on the horizon for this disease
Salvatore Siena, MD, on his study investigating trastuzumab deruxtecan in HER2+ mCRC patients
Dr. Siena, Professor of Medical Oncology, Università degli Studi di Milano, shares design and outcomes from his study presented at ASCO20 investigating Enhertu (trastuzumab deruxtecan) in HER2+ metastatic colorectal cancer patients
Salvatore Siena, MD, on what is next for Enhertu (trastuzumab deruxtecan) in clinical development
Dr. Siena, Professor of Medical Oncology, Università degli Studi di Milano, discusses what is next for Enhertu (trastuzumab deruxtecan) in the clinical development path in colorectal cancer patients
Salvatore Siena, MD, discusses the incidence of HER2+ patients amongst CRC patients
Dr. Siena, Professor of Oncology, Università degli Studi di Milano, discusses the incidence of HER2+ patients amongst colorectal cancer patients and whether Enhertu (trastuzumab deruxtecan) is effective in all HER2+ CRC patients
Salvatore Siena, MD, explains the mechanism of action of trastuzumab deruxtecan and its promise
Dr. Siena, Professor of Medical Oncology, Università degli Studi di Milano, explains the mechanism of action of Enhertu (trastuzumab deruxtecan) and why this particular ADC holds such promise
Tanios Bekaii-Saab, MD, FACP, considers the emerging role of immunotherapy in advanced CRC treatment
Dr. Bekaii-Saab, Professor of Gastrointestinal Cancer, Mayo Clinic, considers the emerging role of immunotherapy in the treatment of advanced colorectal cancer
Tanios Bekaii-Saab, MD, FACP, discusses oral chemotherapy in adjuvant and advanced CRC treatment during the COVID era
Dr. Bekaii-Saab, Professor of Gastrointestinal Cancer, Mayo Clinic, discusses oral chemotherapy in the treatment of adjuvant and advanced colorectal cancer in the COVID-19 Era
Thierry Andre, MD, on evolution of I-O towards the first line treatment of colorectal cancer
Dr. Andre, Professor of Medical Oncology, Sorbonne University, discusses the evolution of I-O towards the first line treatment in colorectal cancer besides pembrolizumab and Keynote-177
Thierry Andre, MD, provides thoughts on how to identify patients with CRC unlikely to respond to I-O
Dr. Andre, Professor of Medical Oncology, Sorbonne University, provides thoughts on how to identify patients with colorectal cancer that are MSI-H/mismatch repair deficient but are unlikely to respond to pembrolizumab or other I-O
Thierry Andre, MD, shares design of the Keynote-177 study in metastatic colorectal cancer
Dr. Andre, Professor of Medical Oncology, Sorbonne University, shares the design of the Keynote-177 study investigating the use of pembrolizumab in MSI-H/mismatch repair deficient metastatic colorectal cancer
Thierry Andre, MD, regarding the outcomes of the Keynote-177 study in metastatic colorectal cancer
Dr. Andre, Professor of Medical Oncology, Sorbonne University, regarding the outcomes of the Keynote-177 study investigating the use of pembrolizumab in MSI-H/mismatch repair deficient metastatic colorectal cancer
Matthew Galsky, MD, discusses how to identify patients that will likely be good responders for I-O
Dr. Galsky, Professor of Medicine, Mount Sinai School of Medicine, discusses how to identify patients that will likely be good responders and therefore, good candidates, for I-O in newly diagnosed urothelial cell carcinoma patients
Howard Hochster, MD, regarding abstract 4009 at ASCO20 looking at the use of ctDNA in CRC patients
Dr. Hochster, Distinguished Professor of Medicine, Rutgers Cancer Institute, regarding abstract 4009 at ASCO20 looking at the use of ctDNA in colorectal cancer patients
Howard Hochster, MD, shares his opinion of the "watch and wait" strategy as presented in the OPRA study
Dr. Hochster, Distinguished Professor of Medicine, Rutgers Cancer Institute, shares his opinion of the "watch and wait" strategy as presented in the OPRA study in rectal cancer patients at ASCO20
Howard Hochster, MD, provides thoughts on the clinical progress of Enhertu (trastuzumab-deruxtecan) in GI cancers
Dr. Hochster, Distinguished Professor of Medicine, Rutgers Cancer Institute, provides thoughts on the clinical progress of Enhertu (trastuzumab-deruxtecan) in GI cancers such as gastric and colorectal cancer presented at ASCO20
Howard Hochster, MD, provides thoughts on the potential practice changing results of the Keynote-177 study
Dr. Hochster, Distinguished Professor of Medicine, Rutgers Cancer Institute, provides thoughts on the potential practice changing results of Keynote-177 investigating pembrolizumab in MSI-High/mismatch repair deficient metastatic colorectal cancer patients
Howard Hochster, MD, discusses the outcomes of the Keynote-177 study in metastatic CRC
Dr. Hochster, Distinguished Professor of Medicine, Rutgers Cancer Institute, discusses the outcomes of the Keynote-177 study investigating the use of pembrolizumab in MSI-High/mismatch repair deficient metastatic colorectal cancer
Alan Venook, MD, provides opinions of the OPRA data in rectal cancer patients presented at ASCO20
Dr. Venook, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, provides opinions of the OPRA data in rectal cancer patients presented at ASCO20
Alan Venook, MD, provides thoughts on the clinical progress of trastuzumab-deruxtecan in GI cancers
Dr. Venook, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, provides thoughts on the clinical progress of Enhertu (trastuzumab-deruxtecan) in GI cancers such as gastric and colorectal cancer
Alan Venook, MD, considers how I-O is evolving towards the first line treatment of colorectal cancer
Dr. Venook, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, considers how I-O is evolving towards the first line treatment of colorectal cancer other than pembrolizumab and the Keynote-177 study
Alan Venook, MD, describes the potential practice changing results of the Keynote-177 study
Dr. Venook, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, describes the potential practice changing results of the Keynote-177 study investigating pembrolizumab in MSI-High/mismatch repair deficient metastatic colorectal cancer patients
Alan Venook, MD, on the Keynote-177 study investigating MSI High/mismatch repair deficient mCRC
Dr. Venook, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, discusses outcomes of the Keynote-177 study investigating the use of pembrolizumab in MSI-High/mismatch repair deficient metastatic colorectal cancer
Alan Venook, MD, discusses uniqueness of MSI-High/mismatch repair deficient CRC patients
Dr. Venook, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, discusses uniqueness of MSI-High/mismatch repair deficient colorectal cancer patients, and how he has historically treated this subgroup of CRC patients.
Tanios Bekaii-Saab, MD, FACP discusses how strategies for the treatment of colorectal cancer patients has changed at the Mayo Clinic as a result of COVID-19
Dr. Bekaii-Saab, Mayo Clinic, discusses how strategies for the treatment of colorectal cancer patients has changed at the Mayo Clinic as a result of COVID-19
Tanios Bekaii-Saab, MD, FACP, describes deintensification strategies in the management of advanced colorectal cancer patients brought to the forefront by COVID-19
Dr. Bekaii-Saab, Mayo Clinic, describes deintensification strategies in the management of advanced colorectal cancer patients brought to the forefront by COVID-19
Tilak Sundaresan, MD, regarding the results of the TAPUR study and its importance to physicians
Dr. Sundaresan, Assistant Chief, Kaiser Permanente San Francisco Medical Center, regarding the results of the TAPUR study presented at ASCO GU 2020 and its importance to physicians
Tilak Sundaresan, MD, determines whether to automatically test for the BRAF mutation in patients
Dr. Sundaresan, Assistant Chief, Kaiser Permanente San Francisco Medical Center, determines whether to automatically test for the BRAF mutation in patients and how this mutation affects treatment of colorectal patients
Tilak Sundaresan, MD, shares how "sided-ness" affects the use of EGFR inhibitors in CRC treatment
Dr. Sundaresan, Assistant Chief, Kaiser Permanente San Francisco Medical Center, shares how the recent clinical studies concerning "sided-ness" affects the use of EGFR inhibitors in the treatment of colorectal cancer
Tilak Sundaresan, MD, discusses combining regorafenib and checkpoint inhibitors in advanced CRC
Dr. Sundaresan, Assistant Chief, Kaiser Permanente San Francisco Medical Center, provided perspective on the combination of regorafenib and checkpoint inhibitors in advanced colorectal cancer
Tilak Sundaresan, MD, elaborates on the influence of cell free DNA when managing CRC patients
Dr. Sundaresan, Assistant Chief, Kaiser Permanente San Francisco Medical Center, elaborates on the influence of cell free DNA when making decisions on the management of colorectal cancer patients
Crystal Denlinger, MD, offers opinion on checkpoint inhibitors being used in anal cancer management
Dr. Denlinger, Chief, Division of Gastrointestinal Medical Oncology, Fox Chase Cancer Center, offers opinion regarding checkpoint inhibitors being used in the management of anal cancer
Crystal Denlinger, MD, discusses quality of life analysis in the IMBRAVE study presented at ASCO GI
Dr Denlinger, Chief, Division of Gastrointestinal Medical Oncology, Fox Chase Cancer Center, discusses quality of life analysis in the IMBRAVE study presented at ASCO GI 2020
Crystal Denlinger, MD, regarding cell free DNA tests and their influence on the treatment of CRC patients
Crystal Denlinger, MD, Chief, Division of Gastrointestinal Medical Oncology, Fox Chase Cancer Center, regarding cell free DNA tests and how they can influence decision making when treating colorectal cancer patients
Crystal Denlinger, MD, comments on the use of fitness trackers in regards to management of CRC
Dr Denlinger, Chief, Division of Gastrointestinal Medical Oncology, Fox Chase Cancer Center, comments on the use of fitness trackers to assess activity level and toxicities regarding the management of colorectal cancer patients
David H Ilson, MD, elaborates on updated data from the BEACON study presented at ASCO GI 2020
Dr. Ilson, Memorial Sloan Kettering Cancer Center, elaborates on updated data regarding the BEACON study presented this year at ASCO GI
Zev Wainberg, MD, on the role of pembrolizumab for MSI high CRC patients and its use in therapy
Dr. Wainberg, Co-Director UCLA GI Oncology Program, Ronald Reagan UCLA Medical center, discusses the appropriate role of pembrolizumab when treating MSI high colorectal cancer patients
Manish Shah, MD, describes BRAF testing tactics and how it affects treatment of CRC patients
Dr. Shah, Director, Weill Cornell Medicine, describes the importance of BRAF testing tactics and how it affects treatment of colorectal cancer patients.
Ryan Corcoran, MD, on the current use of MRD as a valid test for determining GI cancer treatment
Dr. Corcoran, Associate Professor of Medicine, Harvard Medical School, regarding the current use of MRD as a valid test for determining treatment approaches in gastrointestinal cancers
Ryan Corcoran, MD, explains the need for the MRD test in CRC and whether its ready for prime time
Dr. Corcoran, Associate Professor of Medicine, Harvard Medical School, explains reasoning behind the need for the MRD test in colorectal cancer and whether it is ready for prime time
Ryan Corcoran, explains cell free DNA and ways to test for it
Dr. Corcoran, Associate Professor of Medicine, Harvard Medical School, explains cell free DNA and ways to test for it
Richard Kim, MD, on results of phase 1 study regarding locally advanced rectal adenocarcioma
Dr. Kim, Professor of Medicine, University of South Florida College of Medicine, shares results of the phase 1 study regarding preoperative capecitabine and lenvatinib with external radiation therapy in locally advanced rectal adenocarcinoma
Richard Kim, MD, explains how "sided-ness" affects usage of EGFR inhibitors in the treatment of CRC
Dr. Kim, Professor of Medicine, University of South Florida College of Medicine, explains how recent clinical studies concerning "sided-ness" affected his practice in the use of EGFR inhibitors in the treatment of colorectal cancer
Benjamin Weinberg, comments on the use of intratumoral microbiome assessment vs GI tract assessment
Dr. Weinberg, Assistant Professor, Medstar Georgetown University Hospital, comments on the intratumoral microbiome assessment versus the assessment of the microbiome of the gastrointestinal tract
Benjamin Weinberg, MD, on the microbiome and the development of colorectal malignancies
Dr. Weinberg, Professor of Medicine, Georgetown University Hospital, explains the relationship between the microbiome and the development of certain colorectal malignancies
Benjamin Weinberg, MD, on demographic results associated with the microbiome and CRC
Dr. Weinberg, Professor of Medicine, Georgetown University Hospital, describes possible demographic or histologic features associated with findings within the microbiome of patients with colorectal cancer
Crystal Denlinger, MD, explains differentiation of treatment of CRC patients based on age
Dr. Denlinger, Chief, Division of Gastrointestinal Medical Oncology, Fox Chase Cancer Center, explains strategies regarding differentiation of treatment in terms of older vs younger colorectal cancer patients
Crystal Denlinger, MD, shares data regarding first line biliary tract cancer patients
Dr Denlinger, Chief, Division of Gastrointestinal Medical Oncology, Fox Chase Cancer Center, shares data she authored and was presented at ASCO GI 2020 regarding first line biliary tract cancer patients
David H Ilson, MD, shares perspective of the IPACS study regarding stage 4 CRC patients
Dr. Ilson, Memorial Sloan Kettering Cancer Center, shares perspective regarding the IPACS (JCOG 1007) randomized study in stage 4 colorectal cancer patients which investigates chemotherapy alone vs resection and chemotherapy
Ryan Corcoran, MD, elaborates on promising clinical applications of cell free DNA
Dr. Corcoran, Associate Professor of Medicine, Harvard Medical School, elaborates on the promising clinical applications of cell free DNA
Scott Kopetz, MD, explains how BRAF mutations figure into treatment algorithms for CRC
Dr. Kopetz, Professor, GI Medical Oncology, MD Anderson Cancer Center, explains how BRAF mutations figure into treatment algorithms for colorectal cancer (CRC)
Stefan Kasper, MD, provides updates on the BEACON trial in BRAF-mutant CRC
Dr. Kasper, Professor of Oncology, University Hospital West German Cancer Center, Essen, provides updates on the phase III BEACON trial in BRAF-mutant colorectal cancer (CRC)
Deborah Shrag, MD, MPH, on which biomarkers are important in the diagnosis & management of CRC
Dr. Shrag, Professor of Medicine, Harvard Medical School, Chief, Division of Population Sciences, Medical Oncology, Dana-Farber Cancer Institute, provides opinion on which biomarkers are important in the diagnosis and management of colorectal cancer (CRC)
Scott Kopetz, MD, shares updates from the BEACON trial in BRAF-mutant colorectal cancer
Dr. Kopetz, Professor, GI Medical Oncology, MD Anderson Cancer Center, tells us about the updated data from the phase III BEACON trial in BRAF-mutant colorectal cancer
Stefan Kasper, MD, explains the dosing and administration schedule of cetuximab
Dr. Kasper, Professor of Oncology, University Hospital West German Cancer Center, Essen, explains the dosing and administration schedule of cetuximab in combination with chemotherapy in 1st line KRAS wild-type metastatic colorectal cancer
Marwan Fakih, MD, considers implications from the AMG 510 trial
Dr. Fakih, Professor, Department of Medical Oncology & Therapeutics Research, Section Head, GI Medical Oncology, City of Hope, considers the role of KRAS G12C inhibition in the treatment of colorectal cancer and non-small-cell lung cancer (NSCLC) based on data from the AMG 510 trial
Marwan Fakih, MD, on whether MSI-high is a “must-have” biomarker for CRC patients
Dr. Fakih, Professor, Department of Medical Oncology & Therapeutics Research, Section Head, GI Medical Oncology, City of Hope, on MSI-high and other important biomarkers in the diagnosis and management of colorectal cancer patients
Marwan Fakih, MD, discusses the Phase 1 trial evaluating AMG 510 in CRC and NSCLC
Dr. Fakih, Professor, Department of Medical Oncology & Therapeutics Research, Section Head, GI Medical Oncology, City of Hope, discusses the Phase 1 trial evaluating AMG 510 in patients with previously treated KRAS G12C-mutated CRC and NSCLC
Marwan G. Fakih, MD, on combining regorafenib + checkpoint inhibition in advanced CRC
Dr. Fakih, Medical Director, Judy & Bernard Briskin Center for Clinical Research, Co-Director, Gastrointestinal Cancer Program, Section Head, GI Medical Oncology, City of Hope, on whether combining regorafenib with checkpoint inhibition is a promising treatment option for advanced colorectal cancer (CRC)
Marwan G. Fakih, MD, on why AMG 510 seems promising in colorectal and lung cancers
Dr. Fakih, Medical Director, Judy & Bernard Briskin Center for Clinical Research, Co-Director, Gastrointestinal Cancer Program, Section Head, GI Medical Oncology, City of Hope, describes the mechanism of action for AMG 510 and why it seems promising in colorectal and lung cancers
Marwan G. Fakih, MD, describes the role of KRAS inhibitors in colorectal cancer
Dr. Fakih, Medical Director, Judy & Bernard Briskin Center for Clinical Research, Co-Director, Gastrointestinal Cancer Program, Section Head, GI Medical Oncology, City of Hope, describes the role of KRAS inhibitors in colorectal cancer
Leonard Saltz, MD, offers opinion on the value of of liquid biopsy in colorectal cancer treatment
Dr. Saltz, Executive Director for Clinical Value & Sustainability, Head, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center, speculates on the value of liquid biopsy and its role in the treatment of adjuvant and metastatic colorectal cancer (CRC)
Leonard Saltz, MD, offers opinion on molecular profiling in the treatment of CRC
Dr. Saltz, Executive Director for Clinical Value & Sustainability, Head, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center, offers opinion on molecular profiling in the treatment of colorectal cancer (CRC)
Leonard Saltz, MD, considers the complexities of managing metastatic colorectal cancer
Dr. Saltz, Executive Director for Clinical Value & Sustainability, Head, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center, considers the complexities of managing advanced/refractory metastatic colorectal cancer (mCRC)
Leonard Saltz, MD, on whether data presented at ASCO '19 will change the way we treat CRC
Dr. Saltz, Executive Director for Clinical Value & Sustainability, Head, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center, considers whether data presented at the 2019 ASCO Annual Meeting will change the way we treat colorectal cancer
John Strickler, MD, on how next-generation sequencing fits into treatment of mCRC
Dr. Strickler, Assistant Professor of Medicine, Duke Cancer Institute, offers his opinion on how next-generation sequencing (NGS) fits into diagnosis and treatment of metastatic colorectal cancer (mCRC)
Raymond Wadlow, MD, regarding BSC vs. combination checkpoint inhibitors in advanced CRC
Dr. Wadlow, Medical Oncologist, Virginia Cancer Specialist, provides his impression of the Phase 2 study presented at the 2019 Gastrointestinal Cancers Symposium investigating BSC versus combination checkpoint inhibitors in advanced colorectal cancer (CRC)
Richard Kim, MD, regarding the use of regorafenib in treatment of colorectal cancer
Dr. Kim, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assistant Professor of Oncology, University of South Florida College of Medicine, offers his opinion on whether physicians are likely to dose escalate with regorafenib when treating colorectal cancer (CRC)
Axel Grothey, MD, on the CCTG CO.26 trial in advanced refractory CRC presented at GI 2019
Dr. Grothey, Consultant, West Cancer Center, University of Tennessee, shares his impression of the CCTG CO.26 trial comparing durvalumab plus tremelimumab and best supportive care (BSC) versus BSC in advanced refractory colorectal cancer (CRC)
Axel Grothey, MD, on the use of regorafenib in the management of advanced CRC
Dr. Grothey, Consultant, West Cancer Center, University of Tennessee, considers whether the results of ReDOS study have allowed for more effective dosing of regorafenib in the management of advanced colorectal cancer (CRC) patients
Axel Grothey, MD, on patient selection & treatment algorithms in 2nd and 3rd line CRC
Dr. Grothey, Consultant, West Cancer Center, University of Tennessee, shares details regarding patient selection and treatment algorithms in the management of 2nd and 3rd line colorectal cancer patients
Alan Venook, MD, tells us whether ctDNA is a valid treatment response in CRC
Dr. Venook, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, Professor, Department of Medicine, UCSF, tells us whether circulating tumor DNA (ctDNA) is a valid surrogate for minimal residual disease (MRD) or treatment response in colorectal cancer
Axel Grothey, MD, considers the role of circulating tumor DNA (ctDNA)
Dr. Grothey, Consultant, West Cancer Center, University of Tennessee, on whether circulating tumor DNA (ctDNA) is a valid surrogate for minimal residual disease (MRD) or treatment response in colorectal cancer
Alan Venook, MD, discusses next generation sequencing and mCRC treatment
Dr. Venook, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, Professor, Department of Medicine, UCSF, provides opinion on how next generation sequencing (NGS) fits into diagnosis and treatment of metastatic colorectal cancer (mCRC) patients
Axel Grothey, MD, elaborates on next generation sequencing and mCRC
Dr. Grothey, Consultant, West Cancer Center, University of Tennessee, explains how next generation sequencing (NGS) fits into diagnosis and treatment of metastatic colorectal cancer (mCRC) patients
Philip Philip MD, PhD, FRCP, on neoadjuvant chemotherapy & upfront surgery in pancreatic cancer
Dr. Philip, Professor of Oncology, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann Karmanos Cancer Institute, explains how neoadjuvant chemotherapy with gemcitabine and S-1 compares with upfront surgery for resectable pancreatic cancer
Jeffrey A. Meyerhardt, MD, on genetic testing in newly diagnosed mCRC
Dr. Meyerhardt, Professor, Medicine, Harvard Medical School, Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute, shares thoughts on genetic testing in newly diagnosed metastatic colorectal cancer (mCRC) patients
Howard Hochster, MD, on how checkpoint inhibitors are impacting treatment algorithms in mCRC
Dr. Hochster, Associate Director for Clinical Research, Rutgers Cancer Institute of New Jersey, Director of Oncology Research, RWJBarnabas Health, explains how checkpoint inhibitors are impacting treatment algorithms in metastatic colorectal cancer (mCRC)
Jeffrey A. Meyerhardt, MD, shares thoughts on checkpoint inhibitors in adjuvant CRC
Dr. Meyerhardt, Professor, Medicine, Harvard Medical School, Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute offers opinion on whether checkpoint inhibitors will be successful in improving outcomes for adjuvant colorectal cancer (CRC) patients
Howard Hochster, MD, considers next generation sequencing and mCRC treatment decisions
Dr. Hochster, Associate Director for Clinical Research, Rutgers Cancer Institute of New Jersey, Director of Oncology Research, RWJBarnabas Health, considers how next generation sequencing (NGS) fits into diagnosis and treatment of metastatic colorectal cancer (mCRC) patients
Jeffrey A. Meyerhardt, MD, on managing 2nd and 3rd line mCRC patients
Dr. Meyerhardt, Professor, Medicine, Harvard Medical School, Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute, tells us how he manages 2nd and 3rd line metastatic colorectal cancer (mCRC) patients and shares some of the drivers of treatment choice
Howard Hochster, MD, on the management of mCRC patients receiving regorafenib
Dr. Hochster, Associate Director for Clinical Research, Rutgers Cancer Institute of New Jersey, Director of Oncology Research, RWJBarnabas Health, discusses the results of the ReDose study and the management of metastatic colorectal cancer (mCRC) patients receiving regorafenib
Jeffrey A. Meyerhardt, MD, on whether regorafenib is becoming more tolerable for mCRC patients
Dr. Meyerhardt, Professor, Medicine, Harvard Medical School, Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute, considers whether the results of the ReDOS study may make dosing of regorafenib more tolerable for metastatic colorectal cancer (mCRC) patients
Howard Hochster, MD, explains how to manage 2nd and 3rd line mCRC patients
Dr. Hochster, Associate Director for Clinical Research, Rutgers Cancer Institute of New Jersey, Director of Oncology Research, RWJBarnabas Health, describes how he manages 2nd and 3rd line metastatic colorectal cancer (mCRC) patients
Jeffrey A. Meyerhardt, MD, considers the BEACON study in BRAF mutated metastatic colorectal cancer
Dr. Meyerhardt, Professor, Medicine, Harvard Medical School, Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute, discusses the BEACON study investigating the role of encorafenib, binimetinib and cetuximab in patients with BRAF mutated metastatic colorectal cancer (mCRC)
Howard Hochster, MD, regarding the role of genetic testing in mCRC
Dr. Hochster, Associate Director for Clinical Research, Rutgers Cancer Institute of New Jersey, Director of Oncology Research, RWJBarnabas Health, elaborates on genetic testing in newly diagnosed metastatic colorectal cancer (mCRC) patients and how these tests figure into treatment decisions
Atrayee Basu Mallick, MD, shares highlights from the 2018 ASCO Annual Meeting
Dr. Mallick discusses some of the advances in the treatment of colorectal cancer coming out of the 2018 ASCO Annual Meeting
Atrayee Basu Mallick, MD, considers how tumor-sidedness impacts CRC treatment algorithms
Dr. Mallick explains how tumor-sidedness impacts her colorectal cancer (CRC) treatment algorithms
Atrayee Basu Mallick, MD, discusses how nivolumab is incorporated into mCRC treatment algorithms
Dr. Mallick tells us how nivolumab is being incorporated into metastatic colorectal cancer (mCRC) treatment algorithms
Atrayee Basu Mallick, MD, tells us about the outcomes of the Checkmate 142 study in mCRC
Dr. Mallick comments on the outcomes of the Checkmate 142 study looking ipilimumab and nivolumab in metastatic colorectal cancer (mCRC) patients
Atrayee Basu Mallick, MD, on the addition of vemurafenib to the NCCN guidelines for mCRC
Dr. Mallick elaborates on the patient type and setting where vemurafenib has been added to the NCCN guidelines for metastatic colorectal cancer (mCRC) patients
Atrayee Basu Mallick, MD, regarding the impact of stage & mismatch repair status on CRC treatment
Dr. Mallick explains how the stage of colorectal cancer (CRC) and the mismatch repair status impact treatment algorithms
Atrayee Basu Mallick, MD, offers opinion on immunotherapy in colorectal cancer
Dr. Mallick shares her thoughts on the headline “Immunotherapy Now Standard for Some Patients With Colorectal Cancer”
John Leighton, MD, on the headline “Immunotherapy Now Standard for Some Patients With CRC”
Dr. Leighton offers opinion on the headline “Immunotherapy Now Standard for Some Patients With Colorectal Cancer” coming out of the 2018 ASCO Annual Meeting
John Leighton, MD, explains how tumor sidedness impacts CRC treatment algorithms
Dr. Leighton discusses whether tumor sidedness impacts colorectal cancer treatment algorithms
John Leighton, MD, comments on the outcomes of Checkmate 142 in mCRC
Dr. Leighton elaborates on the outcomes of the Checkmate 142 study examining ipilimumab and nivolumab in metastatic colorectal cancer (mCRC) patients
Howard Hochster, MD, regarding the outcomes of the PRODIGY7 study in mCRC
Dr. Hochster provides perspective on the outcomes of the PRODIGY7 study in metastatic colorectal cancer patients using heated single agent oxaliplatin after surgery
Howard Hochster, MD, comments on the VALENTINO study presented at ASCO 2018
Dr. Hochster regarding the effectiveness of maintenance 5FU/LV following FOLFOX + panitumumab induction in metastatic colorectal cancer patients
Howard Hochster, MD, tells us about the outcomes of ECOG-7208 in 2nd line mCRC
Dr. Hochster discusses the outcomes of the ECOG-7208 study in 2nd line metastatic colorectal cancer (mCRC) patients
Richard Goldberg, MD, on the headline, "Immunotherapy Now Standard for Some Patients With CRC"
Dr. Goldberg provides opinion on the headline, "Immunotherapy Now Standard for Some Patients With Colorectal Cancer" coming out of the 2018 ASCO Annual Meeting
Richard Goldberg, MD, elaborates on the outcomes of the PRODIGY7 study in mCRC patients
Dr. Goldberg tells us about the outcomes the PRODIGY7 study in metastatic colorectal cancer (mCRC) patients using heated single agent oxaliplatin after surgery
Al Benson III, MD, FACP, on how tumor-sidedness impacts colorectal cancer treatment algorithms
Dr. Benson, Professor of Medicine, Northwestern University, on how tumor-sidedness impacts colorectal cancer treatment algorithms
Al Benson III, MD, FACP, discusses the role of I-O and immunotherapy combinations when treating CRC
Dr. Benson, Professor of Medicine, Northwestern University, the role of I-O and immunotherapy combinations when treating colorectal cancer
Al Benson, MD, on what molecular markers are most important to test for when treating CRC patients
Dr. Benson, Professor of Medicine, Northwestern University, discusses what molecular markers are most important to test for when treating colorectal cancer patients
Steven J. Cohen, MD, outlines the results of the Checkmate 142 study in mCRC patients
Dr. Cohen, Chief, Medical Oncology & Hematology Division, Jefferson Health/Abington Hospital Vice-Chair, Department of Medical Oncology, Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, tells us about the results of the Checkmate 142 study comparing Yervoy (ipilimumab) + Opdivo (nivolumab) in metastatic colorectcal (mCRC) patients
Steven J. Cohen, MD, discusses vemurafenib and the NCCN guidelines for mCRC patients
Dr. Cohen, Chief, Medical Oncology & Hematology Division, Jefferson Health/Abington Hospital Vice-Chair, Department of Medical Oncology, Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, explains the patient type and setting where Zelboraf (vemurafenib) has been added to the NCCN guidelines for metastatic colorectal cancer (mCRC) patients
Steven J. Cohen, MD, provides insight into sequencing and efficacy outcomes in 2nd line mCRC
Dr. Cohen, Chief, Medical Oncology & Hematology Division, Jefferson Health/Abington Hospital Vice-Chair, Department of Medical Oncology, Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, compares sequencing Stivarga (regorafenib) followed by Erbitux (cetuximab) with the reverse sequence in terms of efficacy outcomes in 2nd line metastatic colorectal cancer (mCRC) patients
Steven J. Cohen, MD, describes how tumor sidedness impacts treatment decisions in mCRC
Dr. Cohen, Chief, Medical Oncology & Hematology Division, Jefferson Health/Abington Hospital Vice-Chair, Department of Medical Oncology, Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, tells us how tumor sidedness affects treatment decisions in metastatic colorectal cancer (mCRC)
Steven J. Cohen, MD, regarding combination atezolizumab + cobimetinib in mCRC patients
Dr. Cohen, Chief, Medical Oncology & Hematology Division, Jefferson Health/Abington Hospital Vice-Chair, Department of Medical Oncology, Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, elaborates on whether the combination of Tecentriq (atezolizumab) and Cotellic (cobimetinib) is effective in treatment of metastatic colorectal cancer (mCRC) patients
Steven J. Cohen, MD, considers the improvement in duration of therapy examined in the ReDOS study
Dr. Cohen, Chief, Medical Oncology & Hematology Division, Jefferson Health/Abington Hospital Vice-Chair, Department of Medical Oncology, Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, discusses the importance of the improvement in duration of therapy as examined in the ReDOS study
Steven J. Cohen, MD, on how to dose patients receiving regorafenib as a result of the ReDOS study
Dr. Cohen, Chief, Medical Oncology & Hematology Division, Jefferson Health/Abington Hospital Vice-Chair, Department of Medical Oncology, Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, explains how to consider dosing patients receiving Stivarga (regorafenib) as a result of the ReDOS study
Philip Philip, MD, PhD, FRCP, discusses the impact of the Checkmate 142 study on mCRC
Dr. Philip, Professor of Medicine, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann Karmanos Cancer Institute, discusses the importance of the Checkmate 142 study (ipilimumab + nivolumab) for metastatic colorectal cancer (mCRC) and how it may impact future therapies
Richard Kim, MD, offers opinion on the ReDOS study and dose escalation of regorafenib
Dr. Kim, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assistant Professor of Oncology, University of South Florida College of Medicine, regarding the ReDOS study and whether, as a result, physicians are more likely to use Stivarga (regorafenib) and dose escalate for hepatocellular carcinoma (HCC) patients & metastatic colorectal cancer (mCRC) patients
Scott Kopetz, MD, PhD, FACP, on the potential of binimetinib + immunotherapy in mCRC patients
Dr. Kopetz, Associate Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, on whether adding binimetinib to immunotherapies improves overall response rates in metastatic colorectal cancer (mCRC) patients
Scott Kopetz, MD, PhD, FACP, regarding molecular profile matching in trials with mCRC patients
Dr. Kopetz, Associate Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses whether molecular profile matching improves outcomes in clinical trials with metastatic colorectal cancer (mCRC) patients
Scott Kopetz, MD, PhD, FACP, on the implications of the BEACON Phase 3 study in BRAF-mutant mCRC
Dr. Kopetz, Associate Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, elaborates on the outcomes of the BEACON Phase 3 study investigating the triple combination of encorafenib, binimetinib, and cetuximab in BRAF-mutant metastatic colorectal cancer (mCRC) patients and how this compares to prior data
Jeffrey Meyerhardt, MD, MPH, on dose escalation of regorafenib as a result of the ReDOS study
Dr. Meyerhardt, Associate Professor, Medicine, Harvard Medical School, Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute, on the results of the ReDOS study and whether, as a result, physicians should feel comfortable using dose escalation of Stivarga (regorafenib)
Jeffrey Meyerhardt, MD, MPH, discusses the length of adjuvant therapy for colorectal cancer patients
Dr. Meyerhardt, Associate Professor, Medicine, Harvard Medical School, Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute, analyzes whether three months of adjuvant therapy is enough for colorectal cancer (CRC) patients
Jeffrey Meyerhardt, MD, MPH, on the implications of the BEACON Phase 3 study in BRAF-mutant mCRC
Dr. Meyerhardt, Associate Professor, Medicine, Harvard Medical School, Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute, elaborates on the outcomes of the BEACON Phase 3 study investigating the triple combination of encorafenib, binimetinib, and cetuximab in BRAF-mutant metastatic colorectal cancer (mCRC) patients
Jeffrey Meyerhardt, MD, MPH, considers the addition of vemurafenib to the NCCN guidelines for mCRC
Dr. Meyerhardt, Associate Professor, Medicine, Harvard Medical School, Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute, explains the patient type and setting where Zelboraf (vemurafenib) has been added to the NCCN guidelines for metastatic colorectal cancer (mCRC) patients
Scott Kopetz, MD, PhD, FACP, explains how nivolumab is being incorporated into mCRC treatment
Dr. Kopetz, Associate Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, shares how Opdivo (nivolumab) is being incorporated into metastatic colorectal cancer (mCRC) treatment algorithms
Scott Kopetz, MD, PhD, FACP, tells us about the outcomes of Checkmate 142 in mCRC patients
Dr. Kopetz, Associate Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, outlines the results of the Checkmate 142 study looking at Yervoy (ipilimumab) and Opdivo (nivolumab) in metastatic colorectal cancer (mCRC) patients
Scott Kopetz, MD, PhD, FACP, considers the addition of vemurafenib to the NCCN guidelines for mCRC
Dr. Kopetz, Associate Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, explains the patient type and setting where Zelboraf (vemurafenib) has been added to the NCCN guidelines for metastatic colorectal cancer (mCRC) patients
Scott Kopetz, MD, PhD, FACP, discusses the incidence of BRAF mutation in CRC patients
Dr. Kopetz, Associate Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, analyzes the incidence of BRAF mutation in colorectal cancer (CRC) patients and what this means for treatment outcomes
Howard Hochster, MD, outlines the results of the Checkmate 142 study in mCRC patients
Dr. Hochster, Professor of Medicine, Medical Oncology Section of Solid Tumor Oncology, Robert Wood Johnson Medical School, Rutgers, tells us about the results of the Checkmate 142 study comparing Yervoy (ipilimumab) + Opdivo (nivolumab) compared to Yervoy (ipilimumab) alone in metastatic colorectcal (mCRC) patients
Howard Hochster, MD, considers patient age and the OncotypeDX recurrence score in CRC
Dr. Hochster, Professor of Medicine, Medical Oncology Section of Solid Tumor Oncology, Robert Wood Johnson Medical School, Rutgers, on whether patient age impacts the reliability of the OncotypeDX recurrence score in colorectal cancer (CRC) patients
Alan Venook, MD, considers how immunotherapy is being integrated into CRC treatment algorithms
Dr. Venook, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, Professor, Department of Medicine, UCSF, describes how immunotherapy is being integrated into colorectal cancer (CRC) treatment algorithms
Alan Venook, MD, on the impact of dose escalation of regorafenib in mCRC patients
Dr. Venook, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, Professor, Department of Medicine, UCSF, explains how dose escalation of Stivarga (regorafenib) in metastatic colorectal cancer (mCRC) patients impacts efficacy and tolerability
Alan Venook, MD, discusses vemurafenib and the NCCN guidelines for mCRC patients
Dr. Venook, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, Professor, Department of Medicine, UCSF, on the patient type and setting where Zelboraf (vemurafenib) has been added to the NCNN guidelines for metastatic colorectal cancer (mCRC) patients
Alan Venook, MD, explains how tumor sidedness affects therapeutic choice
Dr. Venook, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, Professor, Department of Medicine, UCSF, describes how tumor sidedness impacts therapeutic choice
Howard Hochster, MD, elaborates on how tumor sidedness affects therapeutic choice in mCRC patients
Dr. Hochster, Professor of Medicine, Medical Oncology Section of Solid Tumor Oncology, Robert Wood Johnson Medical School, Rutgers, shares thoughts on how tumor sidedness affects therapeutic choice in metastatic colorectal cancer (mCRC) patients
Howard Hochster, MD, on the ReDOS study, regorafenib, and the importance of duration of therapy
Dr. Hochster, Professor of Medicine, Medical Oncology Section of Solid Tumor Oncology, Robert Wood Johnson Medical School, Rutgers, considers the ReDOS study and how 20% of patients remained on Stivarga (regorafenib) for 6+ months
Howard Hochster, MD, offers opinion on the ReDOS study and dose escalation of regorafenib
Dr. Hochster, Professor of Medicine, Medical Oncology Section of Solid Tumor Oncology, Robert Wood Johnson Medical School, Rutgers, discusses the outcomes of the ReDOS study and whether physicians should feel comfortable using dose escalation of Stivarga (regorafenib) in their practice
Jeffrey Meyerhardt, MD, discusses BRAF+ mutation metastatic CRC and vemurafenib
Dr. Meyerhardt, Clinical Director, Gastrointestinal Cancer Center, Associate Professor of Medicine, Harvard Medical School, on adopting vemurafenib in BRAF+ mutation metastatic CRC
Jeffrey Meyerhardt, MD, regarding the optimal duration of therapy in stage III colon cancer patients
Dr. Meyerhardt, Clinical Director, Gastrointestinal Cancer Center, Associate Professor of Medicine, Harvard Medical School, discusses the optimal duration of therapy in stage III colon cancer
Howard Hochster, MD, discusses the optimal duration of FOLFOX therapy in stage III colon cancer
Dr. Hochster, Associate Director for Clinical Services, Yale Cancer Center, on whether stage III colon cancer patients should be treated with 3 months of 6 months of FOLFOX therapy
Howard Hochster, MD, on the impact of SWOG 1406 in treating BRAF mutation positive CRC patients
Dr. Hochster, Associate Director for Clinical Services, Yale Cancer Center, describes his approach to treating BRAF mutation positive CRC patients as a result of the recent SWOG 1406 study
Richard Goldberg, MD, FASCO, regarding the optimal duration of therapy in stage III colon cancer
Dr. Goldberg, Medical Director, West Virginia University Cancer Institute, discusses the optimal duration of therapy in a stage III colon cancer patient
Richard Goldberg, MD, FASCO, defines “high-risk” and “low-risk” stage III colon cancer patients
Dr. Goldberg, Medical Director, West Virginia University Cancer Institute, differentiates between “high-risk” and “low-risk” in a stage III colon cancer patient
Leonard Saltz, MD, reflects on intriguing CRC clinical data presented at ASCO 2017
Dr. Saltz, Chief, Gastrointestinal Oncology Service, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center, describes the most interesting clinical data related to CRC presented at ASCO 2017
Leonard Saltz, MD, offers opinion on the optimal duration of adjuvant chemotherapy in colon cancer
Dr. Saltz, Chief, Gastrointestinal Oncology Service, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center, discusses the role and duration of adjuvant chemotherapy in colon cancer treatment
Philip Philip, MD, on what we’ve learned about the duration of therapy in the adjuvant CRC setting
Dr. Philip, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, elaborates on what we know about duration of therapy in the adjuvant CRC setting
John L. Marshall, MD, discusses which molecular tests to order when determining treatment approach
Dr. Marshall, Chief, Hematology and Oncology, Lombardi Comprehensive Cancer Center, discusses which molecular tests to order when determining treatment approach in a newly diagnosed CRC patient
John L. Marshall, MD, on how to integrate genetic mutations into a treatment decision
Dr. Marshall, Chief, Hematology and Oncology, Lombardi Comprehensive Cancer Center, on how to integrate genetic mutations, and left sided vs right sided CRC, into a treatment decision
Jeffrey A. Meyerhardt, MD, talks about the DFCI wellness study
Dr. Meyerhardt, Associate Professor of Medicine, Dana Farber Cancer Institute, talks about the DFCI wellness study demonstrating that CRC patients with greater physical activity have better outcomes
Philip Philip, MD, shares his perspective on using TAS-102 and regorafenib in CRC patients
Dr. Philip, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, shares his perspective on how to use both TAS-102 and regorafenib in a metastatic CRC patients
Philip Philip, MD, on which molecular tests to order for a newly diagnosed CRC patient
Dr. Philip, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, on which molecular tests to order for a newly diagnosed CRC patient
Philip Philip, MD, on integrating immunotherapy into existing treatment regimens for CRC patients
Dr. Philip, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, on integrating immunotherapy into existing treatment regimens for CRC patients
Alan P. Venook, MD, explains how the 80405 study and its impact on treatment guidelines
Dr. Venook, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, explains how the 80405 study in CRC patients is impacting on treatment guidelines
Alan P. Venook, MD, discusses which molecular tests to order for a newly diagnosed CRC patient
Dr. Venook, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses which molecular tests to order for a newly diagnosed CRC patient
Alan P. Venook, MD, provides his perspective on using TAS-102 and regorafenib in CRC patients
Dr. Venook, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, provides his perspective on how to use both TAS-102 and regorafenib in a metastatic CRC patients
Alan P. Venook, MD, on integrating immunotherapy into existing treatment regimens for CRC patients
Dr. Venook, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, on integrating immunotherapy into existing treatment regimens for CRC patients
Howard S. Hochster, MD, explains the outcomes of the phase 2 study in BRAF mutated CRC patients
Dr. Hochster, Associate Director, Yale Cancer Center, explains the outcomes of the randomized phase 2 study in BRAF mutated CRC patients
Howard S. Hochster, MD, discusses if genetic profiling has changed treating CRC patients
Dr. Hochster, Associate Director, Yale Cancer Center, discusses if genetic profiling has changed the approach to treating CRC patients
Howard S. Hochster, MD, provides perspective on how to use TAS-102 and regorafenib in CRC patients
Dr. Hochster, Associate Director, Yale Cancer Center, provides his perspective on how to use both TAS-102 and regorafenib in a metastatic CRC patients, specifically sequencing
Tanios Bekaii-Saab, MD, on developing effective immunotherapies in CRC patients
Tanios Bekaii-Saab, M.D., Professor of Medicine at Mayo Clinic, provides his perspective progress being made toward selecting the right patient and the right therapeutic approach in CRC patients
Tanios Bekaii-Saab, MD, on progress in developing immunotherapies in non MSI- High CRC patients
Tanios Bekaii-Saab, M.D., Professor of Medicine at Mayo Clinic, provides his perspective on immunotherapy in CRC and what clinicians can look forward to in the future
Bert O’Neill, MD, on making immunotherapy more effective in mCRC
Bert O'Neil, MD, Professor of Oncology, Indiana University, Simon Cancer Center, provides his perspective on the study presented at ASCO 2016 combining a MEK inhibitor and a PD-l inhibitor to make metastatic colorectal cancer patients more responsive to immunotherapy
Alan Venook, MD on whether CALGB/SWOG 80405 study provides guidance on therapeutic regimen
Alan Venook, MD, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center talks about whether the phase 3 CALGB/SWOG 80405 study provides guidance as to which therapeutic regimen should be used in the 1st line setting for mCRC patients
Tanios Bekaii-Saab, MD, on how clinicians factor economics into therapeutic decision making
Tanios Bekaii-Saab, M.D., Professor of Medicine at Mayo Clinic, provides his perspective on how a clinician should factor economics into therapeutic decision making for mCRC patients.
Howard Hochster, MD on the reliability of MSI-High as a predictor of response to nivolumab
Howard Hochster, MD, Professor of Medicine, Yale School of Medicine answers the reliability of MSI-High as a predictor of response to nivolumab (Opdivo) in mCRC
Howard Hochster, MD on the economic benefit seen in CALGB/SWOG 80405
Howard Hochster, MD, Professor of Medicine, Yale School of Medicine discusses how the economic benefit seen in CALGB/SWOG 80405 compares with other factors when determining the right therapeutic choice for mCRC patients
Howard Hochster, MD talks progress in the development of effective non MSI-High immunotherapies
Howard Hochster, MD, Professor of Medicine, Yale School of Medicine on the non MSI-High immunotherapy development progress for CRC patients
Tanios Bekaii-Saab, MD, on performance status when selecting mCRC, 3rd line treatment therapy
Tanios Bekaii-Saab, M.D., Professor of Medicine at Mayo Clinic, talks about the importance of considering performance status when selecting therapy in 3rd line treatment of mCRC
Tanios Bekaii-Saab, MD, comments on dosing regorafenib (Stivarga) in 3rd line treatment of mCRC
Tanios Bekaii-Saab, M.D., Professor of Medicine at Mayo Clinic, comments on dosing regorafenib (Stivarga) in 3rd line treatment of mCRC
Tanios Bekali-Saab, MD, on utilizing regorafenib (Stivarga) and trifluridine (Lonserf)
Tanios Bekaii-Saab, M.D., Professor of Medicine at Mayo Clinic, comments on utilizing regorafenib (Stivarga) and trifluridine (Lonserf) in 3rd line treatment of metastatic colorectal cancer
Tanios Bekali-Saab, MD, comments on sequencing of immunotherapeutic agents in mCRC patients
Tanios Bekaii-Saab, M.D., Professor of Medicine at Mayo Clinic, discusses the importance of giving ipilimumab (Yervoy) prior to nivolumab (Opdivo) in mCRC patients
Tanios Bekaii-Saab, MD on MSI-High as an mCRC response predictor to nivolumab (Opdivo)
Tanios Bekaii-Saab, M.D., Professor of Medicine at Mayo Clinic, shares on the reliability of Microsatellite instability-High (MSI-High) as a predictor of response to nivolumab (Opdivo) in mCRC patients
Tanios Bekali-Saab, MD, tells us whether KRAS is a definitive biomarker in mCRC patients
Tanios Bekali-Saab, MD, Professor of Medicine, Mayo Clinic, comments on whether KRAS can be used to determine treatment approaches knowing that primary origin of tumor also impacts on outcomes in metastatic colorectal cancer
Tanios Bekaii-Saab, MD on outcomes of CALGB/SWOG 80404 and potential impact
Tanios Bekaii-Saab, M.D., Professor of Medicine at Mayo Clinic, provides his perspective on CALGB/SWOG 80405, a Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (m-FOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC) and how it may impact choice of regimen in 1st line setting for metastatic colorectal patients
Tanios Bekaii-Saab, MD, comments on outcomes of CALGB/SWOG 80404 regarding primary site of tumor
Tanios Bekaii-Saab, M.D., Professor of Medicine at Mayo Clinic, provides his perspective on CALGB/SWOG 80405, a Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (m-FOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC)
Alan Venook, MD talks about treatment strategies based on site of primary tumor in CRC patients
Alan Venook, MD, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center discusses treatment strategies because of site of primary tumor (left vs right side) based on CALGB/SWOG 80405 study results
Alan Venook, MD, explains the biological difference between left-sided and right-sided CRC tumors
Alan Venook, MD, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center explains the biological difference between left-sided and right-sided colorectal cancer tumors and how that difference can impact treatment strategy
Alan Venook, MD explains the outcome of phase 3 CALGB/SWOG 80405 study
Alan Venook, MD, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center relays the outcomes of the 3 CALGB/SWOG 80405 study regarding primary site of tumor
Jeffrey A. Meyerhardt, MD explains results from the phase 3 CALGB/SWOG 80405 study
Jeffrey A. Meyerhardt, MD, Associate Professor of Medicine, Dana Farber Cancer Institute, explains the outcomes of the phase 3 CALGB/SWOG 80405 study regarding primary site of tumor
Jeffrey A. Meyerhardt, MD discusses the phase 3 CALGB/SWOG 80405 study
Jeffrey A. Meyerhardt, MD, Associate Professor of Medicine, Dana Farber Cancer Institute discusses if one regimen is preferred over another in the 1st line treatment of metastatic colorectal cancer, due to the phase 3 CALGB/SWOG 80405 study
Jeffrey A. Meyerhardt, MD explains how OS from primary site of tumor may impact treatment
Jeffrey A. Meyerhardt, MD, Associate Professor of Medicine, Dana Farber Cancer Institute, relays how treatment may change based on the overall survival rates shown from primary site of tumor (left vs right side) in metastatic colorectal cancer patients
Jeffrey A. Meyerhardt, MD on the reliability of MSI-High as a predictor of response in mCRC
Jeffrey A. Meyerhardt, MD, Associate Professor of Medicine, Dana Farber Cancer Institute, describes how reliable MSI-High is as a response predictor to Opdivo (nivolumab) in metastatic colorectal cancer
Jeffrey A. Meyerhardt, MD, discusses immunotherapy in MSI-Stable CRC patients
Jeffrey A. Meyerhardt, MD, Associate Professor of Medicine, Dana Farber Cancer Institute, explains the different approaches being studied to make MSI-Stable colorectal cancer tumors more responsive to checkpoint inhibitors
Jeffrey A. Meyerhardt, MD explains integration of Stivarga and Lonserf in later lines of treatment
Jeffrey A. Meyerhardt, MD, Associate Professor of Medicine, Dana Farber Cancer Institute, on the integration process for Stivarga (regorafenib) and Lonserf (trifluridine) into later lines of treatment in metastatic colorectal cancer
Jeffrey A. Meyerhardt, MD weighs in on the economic vs efficacy outcomes in CALGB/SWOG 80405
Jeffrey A. Meyerhardt, MD, Associate Professor of Medicine, Dana Farber Cancer Institute, explains the economic versus efficacy outcomes in CALGB/SWOG 80405
Jeffrey A. Meyerhardt, MD, explains matching mutations and markers to therapies in CRC patients
Jeffrey A. Meyerhardt, MD, Associate Professor of Medicine, Dana Farber Cancer Institute, provides a synopsis of how to find the best therapies for individual patients with colorectal cancer
Philip Philip, MD on Stivarga (regorafenib) dosage in 2nd line treatment of mCRC
Philip Philip, MD, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, discusses optimal dosage for Stivarga (regorafenib) in the 2nd line treatment of metastatic colorectal cancer
Philip Philip, MD explains how to integrate regorafenib and trifluridine for 2nd line mCRC treatment
Philip Philip, MD, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, explains how to integrate Stivarga (regorafenib) and Lonserf (trifluridine) into the 2nd line treatment of metastatic colorectal cancer
Philip Philip, MD on the importance of ipilimumab prior to nivolumab in mCRC patients
Philip Philip, MD, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, discusses the importance of giving Yervoy (ipilimumab) prior to Opdivo (nivolumab) in metastatic colorectal cancer patients
Philip Philip, MD on the reliability of MSI-High as a predictor of response to Opdivo in mCRC
Philip Philip, MD, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, on the reliability of MSI-High as a predictor of response to Opdivo (nivolumab) in metastatic colorectal cancer
Philip Philip, MD discusses phase 3 CALGB/SWOG 80405 study outcomes
Philip Philip, MD, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, discusses phase 3 CALGB/SWOG 80405 study outcomes regarding primary site of tumor
Philip Philip, MD on what is impressing him at ASCO 2016 in CRC
Philip Phillip, MD, Professor of Oncology and Pharmacology, Karmanos Cancer Institute on what is impressing him at ASCO 2016 in CRC
Jeffrey A. Meyerhardt, MD on PD-1 or PD-L1 treatment strategies for MSI-Stable mCRC patients
Jeffrey A. Meyerhardt, MD, Associate Professor of Medicine, Dana Farber Cancer Institute, discusses the top PD-1 or PD-L1 inhibitor treatment strategies for metastatic colorectal cancer patients that are MSI-Stable
Bert O'Neil, MD discusses decision making based on toxicities factor for later lines of mCRC therapy
Bert O'Neil, MD, Professor of Oncology, Indiana University, Simon Cancer Center on how toxicities factor into decision making for later lines of therapy in mCRC
Howard Hochster, MD explains outcomes from the phase 3 CALGB/SWOG 80405 study
Howard Hochster, MD, Professor of Medicine, Yale School of Medicine, on the phase 3 CALGB/SWOG 80405 study outcomes regarding primary site of tumor
Howard Hochster, MD on mCRC treatment changes due to primary site of tumor impact.
Howard Hochster, MD, Professor of Medicine, Yale School of Medicine, discusses treatment changes due to primary site of tumor overall survival impact in mCRC patients
Howard Hochster, MD talks about predictive response therapy based on site of tumor in mCRC
Howard Hochster, MD, Professor of Medicine, Yale School of Medicine on if left versus right-sided primary tumor provides a predictive response to mCRC therapy
Howard Hochster, MD on performance status importance in selecting treatment algorithms
Howard Hochster, MD, Professor of Medicine, Yale School of Medicine weighs in on performance status importance in determining treatment algorithms in later lines of mCRC treatment
Richard Goldberg, MD, talks patient response with the combination of MEK and PD-1 inhibitors
Richard M. Goldberg, MD, FASCO, Physician-in-Chief at Ohio State University Comprehensive Cancer Center explains how the combination of MEK and PD-1 inhibitors make patients more responsive to immunotherapy
Richard Goldberg, MD, discusses selecting the right therapeutic approach for CRC patients
Richard M. Goldberg, MD, FASCO, Physician-in-Chief at Ohio State University Comprehensive Cancer Center, talks about the progress made in selecting the right therapeutic approach for colorectal cancer patients
Richard M. Goldberg, MD, FASCO on KRAS wild type or mutant in right or left-sided mCRC patients
Richard M. Goldberg, MD, FASCO, Physician-in-Chief at Ohio State University Comprehensive Cancer Center, discusses KRAS wild type or mutant in right or left-sided metastatic colorectal cancer patients
Richard M. Goldberg, MD, FASCO on regimen preference in mCRC 1st line treatment
Richard M. Goldberg, MD, FASCO, Physician-in-Chief at Ohio State University Comprehensive Cancer Center, discusses regimen preference in mCRC 1st line treatment based on the phase 3 CALGB/SWOG 80405 study
Richard M. Goldberg, MD, FASCO discusses outcomes of the phase 3 CALGB/SWOG 80405 study
Richard M. Goldberg, MD, FASCO, Physician-in-Chief at Ohio State University Comprehensive Cancer Center, discusses outcomes of the phase 3 CALGB/SWOG 80405 study regarding primary site of tumor
Bert O'Neil, MD on integrating regorafenib and trifluridine into later lines of mCRC treatment
Bert O'Neil, MD, Professor of Oncology, Indiana University, Simon Cancer Center discusses how to integrate regorafenib (Stivarga) and trifluridine (lonserf) into later lines of metastatic colorectal cancer treatment
Bert O'Neil, MD and the combination of ipilimumab with nivolumab in mCRC patients
Bert O'Neil, MD, Professor of Oncology, Indiana University, Simon Cancer Center reviews recent data combining ipilimumab with nivolumab in metastatic colorectal cancer patients
Bert O'Neil, MD on the importance of choosing mCRC treatment based on primary tumor site
Bert O'Neil, MD, Professor of Oncology, Indiana University, Simon Cancer Center discusses importance of the primary site of tumor (left vs right side) when choosing how to treat mCRC
Alan Venook, MD discusses development of immunotherapies for non MSI-High CRC patients
Alan Venook, MD, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center talks about progress being made developing immunotherapies for Non MSI-High colorectal cancer patients
Alan Venook, MD, balancing economics with the efficacy outcomes seen in 80405
Alan Venook, MD, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center on balancing economics with efficacy outcomes in 80405 regarding therapeutic decisions for mCRC patients
Alan Venook, MD relays the optimal dose for regorafenib (Stivarga) in the 2nd line treatment of mCRC
Alan Venook, MD, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center discusses optimal dosage of regorafenib (Stivarga) in the 2nd line treatment of mCRC
Alan Venook, MD on integrating regorafenib and trifluridine into the 2nd line treatment of mCRC
Alan Venook, MD, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center explains how to integrate regorafenib (Stivarga) and trifluridine (Lonserf) into the 2nd line treatment of mCRC
Alan Venook, MD on reliability of MSI-High predictor fpr response to nivolumab (Opdivo) in mCRC
Alan Venook, MD, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center talks about how How reliable is MSI-High is as a predictor of response to nivolumab (Opdivo) in mCRC
Alan Venook, MD relates data presented in EPIC study relates to CALGB/SWOG 80405
Alan Venook, MD, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center talks about how data presented in the EPIC study relates to CALGB/SWOG 80405
Choosing which EGFR inhibitor to use in second line treatment of mCRC patients At ASCO GI 2016
Alan P. Venook, MD of University of California San Francisco discusses which EGFR inhibitor to use in second line treatment of mCRC patients at ASCO GI 2016.
RECOURSE versus CORRECT and CONCUR trials evaluating regorafenib in metastatic CRC at ASCO GI 2016
Alan P. Venook, MD of University of California San Francisco discusses RECOURSE versus CORRECT and CONCUR trials evaluating regorafenib in metastatic CRC at ASCO GI 2016.
Integrating TAS-102 and regorafenib into your therapeutic algorithm for advanced CRC at ASCO GI 2016
Alan P. Venook, MD of University of California San Francisco discusses integrating TAS-102 and regorafenib into your therapeutic algorithm for advanced CRC at ASCO GI 2016.
RECOURSE trial compared to CORRECT and CONCUR evaluating regorafenib in mCRC
Axel Grothey, MD of Mayo Clinic discusses the RECOURSE trial compared to CORRECT and CONCUR evaluating regorafenib in mCRC at ASCO GI 2016.
Biggest questions facing the treatment of colorectal cancer ASCO GI 2016
Axel Grothey, MD of Mayo Clinic discusses the biggest questions facing the treatment of colorectal cancer at ASCO GI 2016.
How has the last 10 years changed the way you treat metastatic colorectal cancer ASCO GI 2016
Axel Grothey, MD of Mayo Clinic discusses how has the last 10 years changed the way you treat metastatic colorectal cancer.
Immunotherapy, MET, and HER 2+ research is the future of colorectal cancer treatment ASCO GI 2016
Axel Grothey, MD of Mayo Clinic discusses immunotherapy, MET, and HER 2+ research is the future of colorectal cancer treatment ASCO GI 2016.
Regorafenib experience and integrating TAS-102 for advanced CRC ASCO GI 2016
Axel Grothey, MD of Mayo Clinic discusses regorafenib experience and integrating TAS-102 for advanced CRC at ASCO GI 2016.
ERCC1 not a valid prognostic or predictive factor in advanced CRC ASCO GI 2016
David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses how ERCC1 not a valid prognostic or predictive factor in advanced CRC at ASCO GI 2016.
STEAM trial may not change treatment paradigm for metastatic CRC ASCO 2016
David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses how the STEAM trial may not change treatment paradigm for metastatic CRC at ASCO 2016.
RAS mutation in patients with metastatic colorectal cancer ASCO GI 2016
David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses RAS mutation in patients with metastatic colorectal cancer at ASCO GI 2016.
ASCO GI 2016 Optimal Dosage Using Regorafenib Colorectal Cancer
Al B. Benson, MD of Northwestern University discusses the optimal dosage using Regorafenib in colorectal cancer at ASCO GI 2016.
Immunotherapy Shows Promise in MSI-High Colorectal Cancer
Davendra Sohal, MD of Cleveland Clinic discusses promise in MSI-High Colorectal Cancer at ASCO GI 2016.
Future of TAS-102 and regorafenib for patients with colorectal cancer
Howard S Hochster, MD of Yale Medical Center discusses the future of TAS-102 and regorafenib for patients with colorectal cancer at ASCO GI 2016.
Follow @OBRTweets